Adriana Carr

Summary

Affiliation: Center of Molecular Immunology
Country: Cuba

Publications

  1. ncbi A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors
    A Carr
    Center of Molecular Immunology, Havana, Cuba
    Hybridoma 19:241-7. 2000
  2. ncbi In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody
    Adriana Carr
    Center of Molecular Immunology, P O Box 16040, Havana 11600, Cuba
    Hybrid Hybridomics 21:463-8. 2002
  3. ncbi Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine
    Adriana Carr
    Center of Molecular Immunology and National Institute of Oncology and Radiobiology, Havana, Cuba
    J Clin Oncol 21:1015-21. 2003
  4. ncbi Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc
    Juan P Oliva
    Department of Nuclear Medicine, National Institute of Oncology and Radiobiology, Plaza, Havana, Cuba
    Breast Cancer Res Treat 96:115-21. 2006
  5. ncbi Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study
    Marta Osorio
    Clinical Trials Unit, National Institute of Oncology and Radiobiology, Havana City, Cuba
    Cancer Biol Ther 7:488-95. 2008
  6. doi Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity
    Lourdes Roque-Navarro
    Antibody Engineering Department, Centre of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, Havana, 11600 Cuba
    Mol Cancer Ther 7:2033-41. 2008

Collaborators

  • Rolando Perez
  • Angel Casaco
  • Circe Mesa
  • Lourdes Roque-Navarro
  • Marta Osorio
  • Juan P Oliva
  • María de Los Angeles Melgares
  • Giselle Saurez
  • Edmundo Rodriguez
  • Enrique Rengifo
  • Elias Gracia
  • Joel Gonzalez
  • Maria Del Carmen Arango
  • Elena Noris
  • Cristina Mateo De Acosta
  • Carlos Toledo
  • Adriana Torriella
  • Jorge Luis González
  • Krittalak Chakrabandhu
  • Imilla Torres
  • Erasmo Gómez
  • Dayamí Alonso
  • Luis Enrique Fernandez
  • Sandra Rodriguez
  • Anne Odile Hueber
  • Joel de Leon
  • Lorenzo Anasagasti
  • Alejandro Joan
  • Irene Alvarez
  • Maiby Orozco
  • Sonia Franco
  • Rosa Ortiz
  • Maria C Rubio
  • Milagros Velazco
  • Gilmara Pimentel
  • Luis E Fernandez
  • Mariela Figueroa
  • Cristina Mateos
  • Xiomara Escobar
  • Ana M Vazquez
  • Joaquin Gonzalez
  • Martha Osorio
  • Mirtha Díaz
  • Zodilina Valdés
  • Lourdes Roque
  • Julia Cruz

Detail Information

Publications6

  1. ncbi A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors
    A Carr
    Center of Molecular Immunology, Havana, Cuba
    Hybridoma 19:241-7. 2000
    ..Immunohistochemical studies in fresh tumor tissues showed that 14F7 MAb strongly recognized in antigen expressed in human breast and melanoma tumors...
  2. ncbi In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody
    Adriana Carr
    Center of Molecular Immunology, P O Box 16040, Havana 11600, Cuba
    Hybrid Hybridomics 21:463-8. 2002
    ..In vivo, the passive treatment with 14F7 MAb produced a strong anti-tumor activity, similar to the anti-tumoral response obtained with standard chemotherapy treatment...
  3. ncbi Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine
    Adriana Carr
    Center of Molecular Immunology and National Institute of Oncology and Radiobiology, Havana, Cuba
    J Clin Oncol 21:1015-21. 2003
    ..A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine...
  4. ncbi Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc
    Juan P Oliva
    Department of Nuclear Medicine, National Institute of Oncology and Radiobiology, Plaza, Havana, Cuba
    Breast Cancer Res Treat 96:115-21. 2006
    ..3 mg or 3 mg of the antibody, was uptaken by 60 and 33.3% of breast tumours, respectively. "In vivo" immune recognition of GM3(NeuGc) in breast tumours reinforces the value of this peculiar target for cancer immunotherapy...
  5. ncbi Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study
    Marta Osorio
    Clinical Trials Unit, National Institute of Oncology and Radiobiology, Havana City, Cuba
    Cancer Biol Ther 7:488-95. 2008
    ..The prognostic value of autoimmunity and the possibilities of dissociating anti-tumor immunity from autoimmunity deserve further research...
  6. doi Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity
    Lourdes Roque-Navarro
    Antibody Engineering Department, Centre of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, Havana, 11600 Cuba
    Mol Cancer Ther 7:2033-41. 2008
    ..This novel mechanism of cell death lets us to support further therapeutic approaches using NGcGM3 as a molecular target for antibody-based cancer immunotherapy...